Could Kimia Farma's losses just be state-enterprise inefficiency, with private K-24 different?

Possibly — which is why this site does not pronounce the sector unprofitable as a verdict. But the burden of proof sits with the seller: while K-24 publishes nothing checkable, "private means efficient" is a claim of the same evidence grade as "three-year payback". Audited losses are hard facts; efficiency is a soft claim; pricing must follow the hard facts.

Against Thailand's Otteri (entry No. 37), which wall is higher?

Indonesia's, completely: Thailand runs a licensing system (a Foreign Business Licence is theoretically obtainable and rarely granted); Indonesian pharmacy retail is a reserved list (no application channel exists at all). The two walls have different shapes, and readers should learn to tell them apart: licensing systems are assessed on approval probability; reserved lists mean turn around immediately.

What about a local partner holding the shares while I fund it?

That is precisely a nominee arrangement, which in a reserved activity amounts to evading the law; the agreement is unenforceable and may carry criminal exposure. This site's answer on nominees is the same in every market: no, and no workaround design is offered.

Opportunity rank #47 (cash-flow board) · Indonesia

Indonesia pharmacy franchising, taken apart: the franchisor says 3 years, the listed incumbent has lost money for three, and foreigners have no ticket at all

Our take: Below the bar

3 years K-24 franchisor-claimed payback (vendor model, no audited data) · Vendor model · Data as of: 2026-01-29

Composite-board score: 2.9 · Where it is strong: Tax friendliness, Hands-off degree · methodology

Data updated: 2026-11-08

The surface story is attractive: K-24 runs 700+ 24-hour pharmacies across 152 cities, franchising since 2007; a 60 sqm outlet costs about Rp1.0–1.2bn all-in with a Rp110–120M franchise fee for six years, and the only payback figure in circulation is the franchisor-side projection of "about three years". All three of this site's tests fail. First, evidence: PT K-24 is private and publishes no per-store P&L; Indonesia has no franchise-disclosure regime, and even the royalty rate cannot be pinned down (1.5% and 1.8% circulate with no formal document). Second, the audited sector numbers point the other way: the listed state incumbent Kimia Farma (KAEF) has posted three consecutive years of net losses (2023 −Rp2.0tn, 2024 −Rp0.84tn, 2025 −Rp0.34tn) on revenue down to Rp9.2tn — in an industry squeezed by public-insurance pricing and drug price ceilings, even the state champion does not make money, and its pharmacy subsidiary does not disclose store economics. Third, eligibility: the Positive Investment List (Presidential Regulation 10/2021) reserves pharmacy drug retail to Indonesian cooperatives and MSMEs, a category that by definition excludes foreign-invested companies, and every pharmacy must be run by a licensed Indonesian pharmacist-in-charge. Rated below the bar as an explainer: its three warnings (vendor-only numbers, a loss-making listed sector, a legal bar on foreign ownership) would each alone suffice to turn a foreign reader away.

In short: four lines first

What it costs to get in

About Rp1.0–1.2bn all-in per store (local franchise basis; no foreign route)

Roughly what it earns

3 years（K-24 franchisor-claimed payback (vendor model, no audited data)）

How much work for you

Medium burden (a licensed pharmacist-in-charge must run operations)

The biggest catch

The numbers that matter

K-24 franchisor-claimed payback (vendor model, no audited data)

3 years

Vendor model As of: 2026-01-29 Source: Fortune Indonesia on the K-24 pharmacy franchise network (29 Jan 2026)

Why we think it makes money

It is the sample case for the "reserved list" lesson — Indonesia's version of a foreign-business act: some retail formats belong by law to domestic MSMEs and cooperatives, and foreign capital does not even get an application form. Reading the reserved list before the returns is the first move in Indonesian consumer retail.

A loss-making listed incumbent is a free industry health check: KAEF's three loss years and a share price down about 40% in a year show pharmacy retail margins being systematically compressed by insurance-channel pricing and drug price ceilings (HET) — franchisees do not get an exemption from the industry's profit pool.

With the Alfamart entry (No. 29) it completes an Indonesian franchising pair: convenience stores are "costed out and unprofitable"; pharmacies are "cannot be costed at all, and cannot be entered" — the same format shell, two entirely different ways to die.

How to actually get in

Foreign investors: no compliant route (pharmacy retail is a reserved activity; nominee arrangements are illegal). This page offers no workaround.
Indonesian readers: the K-24 franchise (rates and payback must be confirmed against the franchisor's current formal documents — the sources this site found contradict each other, which is itself a pre-signing problem to solve).

What it costs, what it earns

Entry amount: About Rp1.0–1.2bn all-in per store (local franchise basis; no foreign route)
How much work for you: Medium burden (a licensed pharmacist-in-charge must run operations)

Costs & taxes, item by item:

Franchise/management fee of Rp110–120M (six-year term) plus a royalty of 1.5% (or 1.8% — basis unresolved).
Initial stock, fit-out, IT and licensing; a licensed pharmacist-in-charge is a statutory standing cost.

Basis: this site uses full-cost net returns only — income minus vacancy, management, maintenance, taxes and insurance, then financing interest, with entry costs in the denominator. See the methodology。

Identity & tax

Status (residency / citizenship)

外资基本关闭（小型零售贸易受限）

This asset does not count toward the channel No status channel

Threshold: —

小型零售贸易对外资受限，加盟登记（STPW）与本地合作要求使外国个人实际上无法以自己名义加盟 Alfamart。本条目主要供在印尼有本地身份或合作方的读者参考，外资读者请直接跳过入场路径。

Source: 印尼贸易部加盟与零售外资规则

Tax (investor level)

本条目的约束在商业条款而非税：阶梯特许权使用费 + 损耗自担的结构，先于税务决定单店盈亏。

特许权使用费按月净销售额阶梯收取（0–4%），卖得越多抽得越多——这是税务之外的第一层利润分配。
单店利润按印尼小企业/个人经营口径纳税；总部不公布单店净利，无从给出税后回报口径。

Double-tax treaties: 同印尼条目通例；本条目为讲解型。

Source: Alfamart 加盟条款；印尼税务总局（DJP）

This section is general information only — not immigration or tax advice. Program rules change frequently; before acting, rely on the official texts and a licensed adviser.

Risks: what could go wrong

This entry is itself the risk statement: vendor-model-only returns, an audited loss-making sector, and a legal bar on foreign ownership — any one of the three would justify rejection; this entry holds all three at once. If these happen, our take changes: If Indonesia revises the reserved list to open pharmacy retail to foreign capital, and a franchisor publishes audited store-level data, this entry is rebuilt.

A disclosure vacuum: in a market with no franchise-disclosure regime, even the franchisor's royalty rate has no consistent formal basis — the signing party is fully exposed informationally to the franchisor. If these happen, our take changes: None (institutional feature).

The industry profit pool is shrinking: the state champion's three loss years and insurance-pricing pressure mean the store-level margin ceiling is descending; the vendor's three-year payback projection was written in a better era. If these happen, our take changes: If KAEF returns to sustained profitability (audited basis), the sector judgment is revised with it.

What we have not verified yet

The following key figures have not yet been verified; the reason is noted for each item.

K-24's actual store-level P&L and closure rate: unpublished by a private company; the "three-year payback" is a vendor claim this site can neither verify nor falsify — which is exactly why it cannot be cited.
Whether the current royalty is 1.5% or 1.8%: the franchisor's formal document governs.

FAQ

Could Kimia Farma's losses just be state-enterprise inefficiency, with private K-24 different?: Possibly — which is why this site does not pronounce the sector unprofitable as a verdict. But the burden of proof sits with the seller: while K-24 publishes nothing checkable, "private means efficient" is a claim of the same evidence grade as "three-year payback". Audited losses are hard facts; efficiency is a soft claim; pricing must follow the hard facts.
Against Thailand's Otteri (entry No. 37), which wall is higher?: Indonesia's, completely: Thailand runs a licensing system (a Foreign Business Licence is theoretically obtainable and rarely granted); Indonesian pharmacy retail is a reserved list (no application channel exists at all). The two walls have different shapes, and readers should learn to tell them apart: licensing systems are assessed on approval probability; reserved lists mean turn around immediately.
What about a local partner holding the shares while I fund it?: That is precisely a nominee arrangement, which in a reserved activity amounts to evading the law; the agreement is unenforceable and may carry criminal exposure. This site's answer on nominees is the same in every market: no, and no workaround design is offered.

Related opportunities

Get the free one-page brief

Get the one-page brief / subscribe for updates

Leave a contact and this page will immediately show a time-limited download link for the brief (valid 24 hours). This site only sends information — it will never pitch you a specific project or pass your contact to any project party.

Data dates are marked per metric; page updated 2026-11-08. This site publishes information and is not investment advice; the corrections channel is in the Disclaimer。